Sort
48,018 grants matching “immunotherapy”
CD19 Directed CAR Therapy
$489,347Carl H. June · University Of Pennsylvania · R01 · FY2014 · CA
Project 4: Translation and preclinical studies of a personalized pancreas cancer vaccine
$489,305William E Gillanders · Washington University · P50 · FY2016 · CA
Regulation of encephalitogenic T cells by CRAC channels
$489,297Stefan Feske · New York University School Of Medicine · R01 · FY2022 · AI
Novel DGKalpha inhibitors and immunotherapy for GBM and melanoma brain metastasis
$489,274Benjamin W. Purow · University Of Virginia · R01 · FY2018 · CA
Function of Wdfy4 in cross-presentation and immunity
$489,211Kenneth M. Murphy · Washington University · R01 · FY2023 · AI
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
$489,159Michael A Caligiuri · Beckman Research Institute/City Of Hope · R01 · FY2021 · CA
Targeting FLT3 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
$489,159Michael A Caligiuri · Beckman Research Institute/City Of Hope · R01 · FY2025 · CA
Peptidoglycan Fragment Library to Investigate Innate Immune Responses
$489,153Catherine Leimkuhler Grimes · University Of Delaware · R01 · FY2023 · GM
Phase II Trial of HOKT3gamma 1 (ALA-ALA) in Type 1 Diabetes
$489,149Kevan C Herold · Yale University · R01 · FY2008 · DK
Nanodelivery platform for antibody drugs targeting NHL
$489,135Masakazu Kamata · University Of Alabama At Birmingham · R01 · FY2020 · CA
Understanding the influence of bone-metastatic prostate cancer and mesenchymal stromal cells on γδ T cells, in the bone microenvironment.
$489,115Daniel Abate-Daga · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2022 · CA
Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors
$489,114Wei R. Chen · University Of Oklahoma · R01 · FY2025 · CA
The role of sex in the life cycle and transmission of Pneumocystis
$489,101Melanie T Cushion · University Of Cincinnati · R01 · FY2019 · HL
Sexual Dimorphism in T Cell Exhaustion and Bladder Cancer
$488,963Zihai Li · Cedars-Sinai Medical Center · P01 · FY2024 · CA
Quantitative modeling of the phenotypic variability of individual T cells and the
$488,944Gregoire Altan-Bonnet · Sloan-Kettering Inst Can Research · R01 · FY2012 · AI
Molecular Imaging Guidance for Potentiating Chemoimmunotherapy in Pancreatic Cancer using Photodynamic Priming
$488,912Girgis Obaid · University Of Texas Dallas · R01 · FY2025 · EB
Translational and Clinical Trial Correlates Core
$488,827Claudia Marcela Diaz-Montero · Cleveland Clinic Lerner Com-Cwru · U54 · FY2024 · CA
Epigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancer
$488,718Ping Chi · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
Regulation of encephalitogenic T cells by CRAC channels
$488,670Stefan Feske · New York University School Of Medicine · R01 · FY2021 · AI
Development of Allogeneic CAR T Cell Therapy for a Functional Cure of HIV Infection
$488,643Todd M Allen · Massachusetts General Hospital · R37 · FY2022 · AI
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
$488,637William Laurence Dahut · Division Of Clinical Sciences - Nci · ZIA · FY2020 · CA
Basic Research Support for the CCR
$488,599Thomas A Misteli · Division Of Basic Sciences - Nci · ZIC · FY2020 · CA
Androgen Activation of Innate Immune Signaling to Enhance Prostate Cancer Immune Response
$488,578Sushant Krishna Kachhap · Johns Hopkins University · R01 · FY2023 · CA
Neuronal and glial interactions of neuropathic pain
$488,534Ru-Rong Ji · Duke University · R01 · FY2017 · DE
Neuronal and glial interactions of neuropathic pain
$488,534Thomas Buchheit · Duke University · R01 · FY2020 · DE